CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 26 enrolled / 26 target
Drug / intervention
phenelzine sulfate +2 moredrug
Likely dose
30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02217709
NCT02217709Phase 2CompletedUpdate Overdue (0.2/mo)Completion was 72mo ago
CompareCT.gov

Phase 2 Trial of Phenelzine in Non-metastatic Recurrent Prostate Cancer

University of Southern California·interventional·Posted Aug 15, 2014·Updated Jun 25, 2026

In Brief

A Phase 2 clinical trial evaluating phenelzine sulfate, laboratory biomarker analysis, and 1 other intervention for Adenocarcinoma of the Prostate and 5 related conditions. Completed, enrolled 26 participants across 4 sites.

Signals

Enrollment appears stalled

Detailed Summary

This phase II trial studies phenelzine sulfate in treating patients with prostate cancer that has not spread to other parts of the body and has come back. Phenelzine sulfate is a type of antidepressant that works by decreasing the amount of a protein called monoamine oxidase (MAO). MAO drugs may have an anticancer effect in prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 15, 2014
Enrollment StartSep 8, 2014
Primary CompletionJun 29, 2020
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 11.9 years ago

Arms & Interventions

Treatment (phenelzine sulfate)experimental

Patients receive phenelzine sulfate 30 mg by mouth (PO) twice daily (BID) (starting dose of 15 mg daily escalated to 30 mg BID over 16 plus or minus 5 days). Patients who have been treated at 30 mg BID for over 3 cycles with resolution of any and all toxicities to grade \< or = 1 may increase the dose to a maximum of 45 mg BID at the discretion of the treating investigator. Treatment may continue in the absence of disease progression or unacceptable toxicity.

Drug: phenelzine sulfateOther: laboratory biomarker analysisOther: questionnaire administration

Interventions

phenelzine sulfatedrug

Given by mouth

laboratory biomarker analysisother

Correlative studies

questionnaire administrationother

Ancillary studies